These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 30530403)

  • 1. Five-year safety and performance data of a novel third-generation novolimus-eluting bioresorbable scaffold in single de novo lesions.
    Verheye S; Costa RA; Schofer J; Ormiston JA; Maeng M; Dudek D; Skurk C; Botelho RV; Costa JR; Chamié D; Abizaid AS; Boersma E; Abizaid AA
    EuroIntervention; 2019 Oct; 15(8):685-687. PubMed ID: 30530403
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial.
    Serruys PW; Chevalier B; Sotomi Y; Cequier A; Carrié D; Piek JJ; Van Boven AJ; Dominici M; Dudek D; McClean D; Helqvist S; Haude M; Reith S; de Sousa Almeida M; Campo G; Iñiguez A; Sabaté M; Windecker S; Onuma Y
    Lancet; 2016 Nov; 388(10059):2479-2491. PubMed ID: 27806897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serial Multimodality Imaging and 2-Year Clinical Outcomes of the Novel DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold System for the Treatment of Single De Novo Coronary Lesions.
    Abizaid A; Costa RA; Schofer J; Ormiston J; Maeng M; Witzenbichler B; Botelho RV; Costa JR; Chamié D; Abizaid AS; Castro JP; Morrison L; Toyloy S; Bhat V; Yan J; Verheye S
    JACC Cardiovasc Interv; 2016 Mar; 9(6):565-74. PubMed ID: 27013155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.
    Serruys PW; Chevalier B; Dudek D; Cequier A; Carrié D; Iniguez A; Dominici M; van der Schaaf RJ; Haude M; Wasungu L; Veldhof S; Peng L; Staehr P; Grundeken MJ; Ishibashi Y; Garcia-Garcia HM; Onuma Y
    Lancet; 2015 Jan; 385(9962):43-54. PubMed ID: 25230593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent in routine PCI: three-year clinical outcomes from the AIDA trial.
    Kerkmeijer LSM; Tijssen RYG; Hofma SH; van der Schaaf RJ; Arkenbout KE; Kraak RP; Weevers A; Piek JJ; de Winter RJ; Tijssen JGP; Henriques JPS; Wykrzykowska JJ;
    EuroIntervention; 2019 Sep; 15(7):603-606. PubMed ID: 31147304
    [No Abstract]   [Full Text] [Related]  

  • 6. Post-dilatation after implantation of bioresorbable everolimus- and novolimus-eluting scaffolds: an observational optical coherence tomography study of acute mechanical effects.
    Blachutzik F; Boeder N; Wiebe J; Mattesini A; Dörr O; Most A; Bauer T; Röther J; Tröbs M; Schlundt C; Achenbach S; Hamm CW; Nef HM
    Clin Res Cardiol; 2017 Apr; 106(4):271-279. PubMed ID: 27757522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subacute thrombosis after primary percutaneous coronary intervention with bioresorbable vascular scaffold implantation.
    Tomaniak M; Kochman J; Kołtowski Ł; Pietrasik A; Rdzanek A
    Kardiol Pol; 2015; 73(4):300. PubMed ID: 25892264
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of a bioresorbable novolimus eluting vascular scaffold fails a hybrid PCI strategy with drug eluting stent.
    Schneider VS; Skurk C; Riedel M; Abdelwahed YS; Landmesser U; Leistner DM
    Clin Res Cardiol; 2017 Jul; 106(7):557-559. PubMed ID: 28374059
    [No Abstract]   [Full Text] [Related]  

  • 9. A Randomized Trial Comparing the NeoVas Sirolimus-Eluting Bioresorbable Scaffold and Metallic Everolimus-Eluting Stents.
    Han Y; Xu B; Fu G; Wang X; Xu K; Jin C; Tao L; Li L; Hou Y; Su X; Fang Q; Chen L; Liu H; Wang B; Yuan Z; Gao C; Zhou S; Sun Z; Zhao Y; Guan C; Stone GW;
    JACC Cardiovasc Interv; 2018 Feb; 11(3):260-272. PubMed ID: 29413240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of bioresorbable scaffolds: hype or hope?
    Tan HC; Ananthakrishna R
    Singapore Med J; 2017 Sep; 58(9):512-515. PubMed ID: 27868135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of the novel sirolimus-eluting bioresorbable scaffold for the treatment of de novo coronary artery disease: One-year results from a prospective patient-level pooled analysis of NeoVas trials.
    Xu K; Fu G; Xu B; Zhou Y; Su X; Liu H; Zhang Z; Yu B; Wang X; Han Y;
    Catheter Cardiovasc Interv; 2019 Feb; 93(S1):832-838. PubMed ID: 30888736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-generation drug-eluting stents and bioresorbable vascular scaffolds in patients with diabetes.
    Schoos MM; Clemmensen P; Dangas GD
    JACC Cardiovasc Interv; 2014 May; 7(5):494-6. PubMed ID: 24852803
    [No Abstract]   [Full Text] [Related]  

  • 13. Everolimus- Versus Novolimus-Eluting Bioresorbable Scaffolds for the Treatment of Coronary Artery Disease: A Matched Comparison.
    Wiebe J; Dörr O; Ilstad H; Husser O; Liebetrau C; Boeder N; Bauer T; Möllmann H; Kastrati A; Hamm CW; Nef HM
    JACC Cardiovasc Interv; 2017 Mar; 10(5):477-485. PubMed ID: 28216214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overlapping implantation of bioresorbable novolimus-eluting scaffolds: an observational optical coherence tomography study.
    Blachutzik F; Boeder N; Wiebe J; Mattesini A; Dörr O; Most A; Bauer T; Tröbs M; Röther J; Schlundt C; Achenbach S; Hamm C; Nef H
    Heart Vessels; 2017 Jul; 32(7):781-789. PubMed ID: 28004176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic Outcomes of Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ABSORB III Trial.
    Baron SJ; Lei Y; Chinnakondepalli K; Vilain K; Magnuson EA; Kereiakes DJ; Ellis SG; Stone GW; Cohen DJ;
    JACC Cardiovasc Interv; 2017 Apr; 10(8):774-782. PubMed ID: 28427593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II Trial).
    Chevalier B; Cequier A; Dudek D; Haude M; Carrie D; Sabaté M; Windecker S; Reith S; de Sousa Almeida M; Campo G; Iñiguez A; Onuma Y; Serruys PW
    EuroIntervention; 2018 Jan; 13(13):1561-1564. PubMed ID: 29094677
    [No Abstract]   [Full Text] [Related]  

  • 17. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results.
    Verheye S; Ormiston JA; Stewart J; Webster M; Sanidas E; Costa R; Costa JR; Chamie D; Abizaid AS; Pinto I; Morrison L; Toyloy S; Bhat V; Yan J; Abizaid A
    JACC Cardiovasc Interv; 2014 Jan; 7(1):89-99. PubMed ID: 24139932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Six-month outcomes of the XINSORB bioresorbable sirolimus-eluting scaffold in treating single de novo lesions in human coronary artery.
    Wu Y; Shen L; Ge L; Wang Q; Qian J; Zhang F; Yao K; Huang D; Chen Y; Ge J
    Catheter Cardiovasc Interv; 2016 Mar; 87 Suppl 1():630-7. PubMed ID: 26864162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-life data regarding acute procedural success and 1-year clinical outcome of desolve bioresorbable scaffolds.
    Gunes HM; Gokdeniz T; Kizilirmak Yilmaz F; Demir GG; Guler E; Babur Guler G; Karaca O; Cakal B; Omaygenç MO; İbişoğlu E; Boztosun B
    J Interv Cardiol; 2017 Jun; 30(3):189-194. PubMed ID: 28440067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial.
    Haude M; Ince H; Abizaid A; Toelg R; Lemos PA; von Birgelen C; Christiansen EH; Wijns W; Neumann FJ; Kaiser C; Eeckhout E; Lim ST; Escaned J; Garcia-Garcia HM; Waksman R
    Lancet; 2016 Jan; 387(10013):31-9. PubMed ID: 26470647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.